Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Fan, Nai Jun ^a   Gao, Chun Fang ^a   Zhao, Guang ^a   Wang, Xiu Li ^a   Liu, Qing Yin ^a  

^a No 150 Central Hospital of PLA   (China)

Author keywords

Breast neoplasms; Diagnosis; Matrix assisted laser desorption ionization time of flight mass spectrometry; Proteomics

Indexed keywords

PROTEOME; TUMOR MARKER;

AREA UNDER THE CURVE; ARTICLE; BIOLOGY; BLOOD; BREAST TUMOR; FEMALE; HUMAN; MAGNETISM; MASS SPECTROMETRY; METHODOLOGY; MIDDLE AGED; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE;

AREA UNDER CURVE; BREAST NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; HUMANS; MAGNETICS; MIDDLE AGED; PROTEOME; PROTEOMICS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SUPPORT VECTOR MACHINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84864293084     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-45     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Elmore JG, Armstrong K, Lehman CD, Fletcher SW. Screening for breast cancer. Jama 2005, 293:1245-1256. 10.1001/jama.293.10.1245, 3149836, 15755947.
3. Duric VM, Stockler MR, Heritier S, Boyle F, Beith J, Sullivan A, Wilcken N, Coates AS, Simes RJ. Patients' preferences for adjuvant chemotherapy in early breast cancer: what makes AC and CMF worthwhile now?. Ann Oncol 2005, 16:1786-1794. 10.1093/annonc/mdi370, 16126738.
4. Geiser WR, Haygood TM, Santiago L, Stephens T, Thames D, Whitman GJ. Challenges in mammography: part 1, artifacts in digital mammography. AJR Am J Roentgenol 2011, 197:W1023-1030. 10.2214/AJR.10.7246, 22109316.
5. Balafar MA. Spatial based expectation maximizing (EM). Diagn Pathol 2011, 6:103. 10.1186/1746-1596-6-103, 3219670, 22029864.
6. Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW. Infiltrating lobular carcinoma of the breast. Histopathology 1982, 6:149-161. 10.1111/j.1365-2559.1982.tb02712.x, 7076138.
7. Silverstein MJ, Lewinsky BS, Waisman JR, Gierson ED, Colburn WJ, Senofsky GM, Gamagami P. Infiltrating lobular carcinoma. Is it different from infiltrating duct carcinoma?. Cancer 1994, 73:1673-1677. 10.1002/1097-0142(19940315)73:6<1673::AID-CNCR2820730620>3.0.CO;2-B, 8156495.
8. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E. Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 1999, 91:2020-2028. 10.1093/jnci/91.23.2020, 10580027.
9. Collett K, Stefansson IM, Eide J, Braaten A, Wang H, Eide GE, Thoresen SO, Foulkes WD, Akslen LA. A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 2005, 14:1108-1112. 10.1158/1055-9965.EPI-04-0394, 15894660.
10. Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol 2012, 24:44-48. 10.1097/GCO.0b013e32834da4b1, 22123219.
11. Lale S, Kure K, Lingamfelter D. Challenges to diagnose metaplastic carcinoma of the breast through cytologic methods: an eight-case series. Diagn Pathol 2011, 6:7. 10.1186/1746-1596-6-7, 3033233, 21244696.
12. Phizicky E, Bastiaens PI, Zhu H, Snyder M, Fields S. Protein analysis on a proteomic scale. Nature 2003, 422:208-215. 10.1038/nature01512, 12634794.
13. Issaq HJ, Xiao Z, Veenstra TD. Serum and plasma proteomics. Chem Rev 2007, 107:3601-3620. 10.1021/cr068287r, 17636887.
14. Dai Y, Hu C, Wang L, Huang Y, Zhang L, Xiao X, Tan Y. Serum peptidome patterns of human systemic lupus erythematosus based on magnetic bead separation and MALDI-TOF mass spectrometry analysis. Scand J Rheumatol 2010, 39:240-246. 10.3109/03009740903456292, 20166849.
15. Liu LH, Shan BE, Tian ZQ, Sang MX, Ai J, Zhang ZF, Meng J, Zhu H, Wang SJ. Potential biomarkers for esophageal carcinoma detected by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem Lab Med 2010, 48:855-861.
16. Sui W, Huang L, Dai Y, Chen J, Yan Q, Huang H. Proteomic profiling of renal allograft rejection in serum using magnetic bead-based sample fractionation and MALDI-TOF MS. Clin Exp Med 2010, 10:259-268. 10.1007/s10238-010-0094-5, 20376689.
17. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 2005, 4:972-981. 10.1021/pr050046x, 15952745.
18. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 2004, 76:1560-1570. 10.1021/ac0352171, 15018552.
19. Omenn GS. The human proteome organization plasma proteome project pilot phase: reference specimens, technology platform comparisons, and standardized data submissions and analyses. Proteomics 2004, 4:1235-1240. 10.1002/pmic.200300686, 15188423.
20. Yao N, Chen H, Lin H, Deng C, Zhang X. Enrichment of peptides in serum by C(8)-functionalized magnetic nanoparticles for direct matrix-assisted laser desorption/ionization time-of-flight mass spectrometry analysis. J Chromatogr A 2008, 1185:93-101. 10.1016/j.chroma.2008.01.047, 18262195.
21. Whiteaker JR, Zhao L, Zhang HY, Feng LC, Piening BD, Anderson L, Paulovich AG. Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers. Anal Biochem 2007, 362:44-54. 10.1016/j.ab.2006.12.023, 1852426, 17241609.
22. West-Norager M, Kelstrup CD, Schou C, Hogdall EV, Hogdall CK, Heegaard NH. Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 847:30-37. 10.1016/j.jchromb.2006.09.048, 17112795.
23. Shin S, Cazares L, Schneider H, Mitchell S, Laronga C, Semmes OJ, Perry RR, Drake RR. Serum biomarkers to differentiate benign and malignant mammographic lesions. J Am Coll Surg 2007, 204:1065-1071. discussion 1071-1063, 10.1016/j.jamcollsurg.2007.01.036, 17481542.
24. Baumann S, Ceglarek U, Fiedler GM, Lembcke J, Leichtle A, Thiery J. Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 2005, 51:973-980. 10.1373/clinchem.2004.047308, 15845803.
25. Ketterlinus R, Hsieh SY, Teng SH, Lee H, Pusch W. Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. Biotechniques 2005, 37-40.
26. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, Venge P, Arnlov J. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 2008, 358:2107-2116. 10.1056/NEJMoa0707064, 18480203.
27. Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, Mueller GA, Kuczyk M, Mueller CA. Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis. Proteomics 2006, 6:697-708. 10.1002/pmic.200500033, 16252305.
28. Cheng AJ, Chen LC, Chien KY, Chen YJ, Chang JT, Wang HM, Liao CT, Chen IH. Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. Clin Chem 2005, 51:2236-2244. 10.1373/clinchem.2005.052324, 16239339.
29. Alagaratnam S, Mertens BJ, Dalebout JC, Deelder AM, van Ommen GJ, den Dunnen JT, t Hoen PA. Serum protein profiling in mice: identification of Factor XIIIa as a potential biomarker for muscular dystrophy. Proteomics 2008, 8:1552-1563. 10.1002/pmic.200700857, 18409166.
30. Chinello C, Gianazza E, Zoppis I, Mainini V, Galbusera C, Picozzi S, Rocco F, Galasso G, Bosari S, Ferrero S, et al. Serum biomarkers of renal cell carcinoma assessed using a protein profiling approach based on ClinProt technique. Urology 2010, 75:842-847. 10.1016/j.urology.2009.09.050, 19963255.
31. Du J, Yang S, Lin X, Bu L, Nan Y, Huo S, Shang W. Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer. Diagn Pathol 2010, 5:60. 10.1186/1746-1596-5-60, 2955651, 20854674.
32. Gast MC, Zapatka M, van Tinteren H, Bontenbal M, Span PN, Tjan-Heijnen VC, Knol JC, Jimenez CR, Schellens JH, Beijnen JH. Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. J Cancer Res Clin Oncol 2011, 137:1773-1783. 10.1007/s00432-011-1055-4, 3205273, 21913038.
33. Liu C. The application of SELDI-TOF-MS in clinical diagnosis of cancers. J Biomed Biotechnol 2011, 2011:245821. 3114543, 21687541.
34. Tooker BC, Newman LS, Bowler RP, Karjalainen A, Oksa P, Vainio H, Pukkala E, Brandt-Rauf PW. Proteomic detection of cancer in asbestosis patients using SELDI-TOF discovered serum protein biomarkers. Biomarkers 2011, 16:181-191. 10.3109/1354750X.2010.543289, 21231887.
35. Fan NJ, Gao CF, Wang XL. Identification of Regional Lymph Node Involvement of Colorectal Cancer by Serum SELDI Proteomic Patterns. Gastroenterol Res Pract 2011, 2011:784967. 3255105, 22253617.
36. Engwegen JY, Gast MC, Schellens JH, Beijnen JH. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry. Trends Pharmacol Sci 2006, 27:251-259. 10.1016/j.tips.2006.03.003, 16600386.
37. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577. 10.1016/S0140-6736(02)07746-2, 11867112.
38. Chen YD, Zheng S, Yu JK, Hu X. Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 2004, 10:8380-8385. 10.1158/1078-0432.CCR-1162-03, 15623616.
39. Liu XP, Shen J, Li ZF, Yan L, Gu J. A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry. Cancer Invest 2006, 24:747-753. 10.1080/07357900601063873, 17162557.
40. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006, 52:1223-1237. 10.1373/clinchem.2006.069252, 16644871.
41. Navare A, Zhou M, McDonald J, Noriega FG, Sullards MC, Fernandez FM. Serum biomarker profiling by solid-phase extraction with particle-embedded micro tips and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom 2008, 22:997-1008. 10.1002/rcm.3462, 2665883, 18320548.
42. Cho WC. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007, 6:25. 10.1186/1476-4598-6-25, 1852117, 17407558.